Cas:20915-45-1 glyoxal-bis-(methyl-phenyl-hydrazone) manufacturer & supplier

We serve Chemical Name:glyoxal-bis-(methyl-phenyl-hydrazone) CAS:20915-45-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

glyoxal-bis-(methyl-phenyl-hydrazone)

Chemical Name:glyoxal-bis-(methyl-phenyl-hydrazone)
CAS.NO:20915-45-1
Synonyms:glyoxal bis(N-Methyl-N-phenyl hydrazone);GLYOXAL BIS(N-METHYL-N-PHENYLHYDRAZONE)
Molecular Formula:C16H18N4
Molecular Weight:266.34100
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:31.20000
Exact Mass:266.15300
LogP:3.23080

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like glyoxal bis(N-Methyl-N-phenyl hydrazone) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,GLYOXAL BIS(N-METHYL-N-PHENYLHYDRAZONE) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,GLYOXAL BIS(N-METHYL-N-PHENYLHYDRAZONE) Use and application,glyoxal bis(N-Methyl-N-phenyl hydrazone) technical grade,usp/ep/jp grade.


Related News: The Company��s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. glyoxal-bis-(methyl-phenyl-hydrazone) manufacturer Inceptua Medicines Access is a business unit of the Inceptua Group. It offers full access solutions for the design, implementation and delivery of Pre-approval and Medicines Access Programs on behalf of biopharmaceutical companies. glyoxal-bis-(methyl-phenyl-hydrazone) supplier The travel restrictions will take effect on Tuesday, Prime Minister Chung Sye-kyun said, as the number of people testing positive for the coronavirus in South Korea increased to 15. glyoxal-bis-(methyl-phenyl-hydrazone) vendor GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.�� glyoxal-bis-(methyl-phenyl-hydrazone) factory The Company��s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.